secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001683168-23-000813
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports Q3 net loss of $2.85M; cash $17.5M; hires Lee Arnold as CSO
--------------------------------------------------------------------------------

- Net loss increased to ~$2.85M for quarter vs $2.53M year ago; operating expenses rose 12% to $2.85M.
- Cash balance ~$17.5M at Dec 31, 2022; raised $8.9M net via ATM equity offers in nine fiscal months.
- Hired Lee Arnold, PhD (inventor of Tarceva) as Chief Scientific Officer; contracted NAMSA for planned oncology Hemopurifier trial.
- COVID-19 ICU trial in India continues (one patient treated); preclinical mPox and Long COVID studies underway.
- No government contract revenue recorded; $574K deferred revenue expected after NCI closeout review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/0001683168-23-000813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-000813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer